Skip to main content
Download PDF

Luteolin: a flavonoid with a multifaceted anticancer potential

Cancer Cell International volume 22, Article number: 386 (2022) Cite this article

Abstract

Therapeutic effect of phytochemicals has been emphasized in the traditional medicine owing to the presence of bioactive molecules, such as polyphenols. Luteolin is a flavone belonging to the flavonoid class of polyphenolic phytochemicals with healing effect on hypertension, inflammatory disorders, and cancer due to its action as pro-oxidants and antioxidants. The anticancer profile of luteolin is of interest due to the toxic effect of contemporary chemotherapy paradigm, leading to the pressing need for the development and identification of physiologically benevolent anticancer agents and molecules. Luteolin exerts anticancer activity by downregulation of key regulatory pathways associated with oncogenesis, in addition to the induction of oxidative stress, cell cycle arrest, upregulation of apoptotic genes, and inhibition of cell proliferation and angiogenesis in cancer cells. In this review, we discuss about the anticancer profile of luteolin.

Introduction

Cancer claims a towering morbidity and mortality rate worldwide. As per the report published by World Health Organization on 3 February 2022, cancer is the leading cause of death around the globe with 10 million total deaths alone in the year 2020 due to lung cancer (1.80 million deaths of 2.21 million cases), colon cancer (0.91 million deaths of 1.93 million cases), and breast cancer (0.68 million deaths of 2.26 million cases) (https://www.who.int/news-room/fact-sheets/detail/cancer). Chemotherapy has served as a silver lining to the cancer patients; however, the side effects and a sizeable mortality rate demands alternative treatment regime with physiologically safe drugs to which the naturally occurring compounds present a robust candidature. Furthermore, the evolution of drug resistance in cancer cells aggravates the need for safer alternatives with optimal efficacy for sensitizing the cancer cells towards conventional drugs [1].

Phytochemicals offer a resolute anticancer profile by providing novel pharmacophores and bioactive molecules that not only inhibit the development and progression of cancers by modulating the key regulatory pathways but ameliorate the chemo-sensitization of cancer cells. In addition to this, anticancer phytochemicals simultaneously target diverse, interconnected oncological pathways that further prevent the relapse and evade the resistance mechanisms in oncologic cells [2]. Of the diverse nature of anti-oncologic phytochemicals, the phenolics present a commendable profile with multifaceted modes of action towards cancer-associated pathways.

Luteolin is a phenolic phytochemical belonging to the flavone class of flavonoids with a notable therapeutic potential which has been utilized in the management of carcinogenesis by the induction of apoptosis, activation of cell cycle arrest, mitigation of angiogenesis, metastasis, and cell proliferation [3]. The anticancer effects of Luteolin have been observed in malignancies where it effectively modulates the expression of multifaceted oncological pathways that work in tandem to manifest tumorigenesis. Luteolin induces mitochondrial dysfunction and activates the endoplasmic reticulum stress response in glioblastoma cells, which triggers the generation of intracellular reactive oxygen species (ROS) [4]. These events further activate the expression of stress-related proteins by mediating the phosphorylation of PERK, ATF4, eIF2α, and cleaved-caspase 12. Luteolin is known to reverse epithelial-to-mesenchymal transition (EMT), which is associated with the cancer cell progression and metastasis. These events are caused by the dwindling of cytoskeleton and by upregulating the biomarker E-cadherin expression, followed by a significant downregulation of the N-cadherin and vimentin expression [5]. Furthermore, luteolin holds potential to improve the spinal damage and brain trauma caused by 1-methyl-4-phenylpyridinium due to its excellent neuroprotective properties. Luteolin-mediated sensitization of cancer cells ameliorates the chemotherapy-induced cytotoxicity due to the downregulation and suppression of cellular pathways such as nuclear factor kappa B (NF-kB), phosphatidylinositol 3’-kinase (PI3K)/Akt, and X-linked inhibitor of apoptosis protein (XIAP) [6]. Owing to a remarkable anticancer profile, luteolin serves as an attractive molecule for the development of impending anticancer drugs. In this review, we discus about the robust anticancer profile of luteolin. The signaling pathways affected by luteolin are depicted in  Fig. 1.

Fig. 1
figure 1

Signaling pathways affected by luteolin

Full size image

Luteolin as redox stress regulator

Onset of redox stress resulting in the cascade of several deleterious biochemical and physiological events marks the commencement of oncogenesis. It mainly arises from the generation of a diverse group of highly reactive, oxygen containing species with a short lifespan that serve as second messengers for cellular signaling. These include hydrogen peroxide (H2O2), hydroxyl radical (.OH), singlet oxygen (1O2), superoxide radical (O2-), and lipid peroxyl radical (LOO). The reactive oxygen species (ROS) are known to manifest irreparable damage to DNA, proteins, and lipids. that eventually causes diseases including cancer.

The regulation of redox stress by luteolin plays an important role in exerting the anticancer activity, by exerting the antioxidant effect arising due to the oxidation of its phenolic groups where the hydrogen atom may be donated to the free radicals. Notably, luteolin exhibits pro-oxidant properties that support the onset of apoptosis in tumor cells due to ROS-mediated damage to nucleotides and proteins, which also interferes with cellular signaling by ROS production that plays an important role in triggering apoptosis. The main pathways involved in this event include suppression of NF-kB pathway, and activation of JNK pathway that induces TNF-mediated cytotoxicity to cancer cells.

Kang et al. [7] reported luteolin-induced redox stress for the induction of apoptotic cell death in human colon cancer cells. The onset of apoptosis occurs due to the activation of mitochondria-mediated caspase pathway in HT-29 cells. Furthermore, the membrane action potential of mitochondria depletes in the presence of luteolin, Ca2+ levels and Bax expression upregulate, the levels of caspase-3 and caspase-9 increase, while the downregulation of Bcl-2 expression occurs. These events cause the cytosolic release of cytochrome c from mitochondria that onsets the production of intracellular and mitochondrial ROS scavenging antioxidant enzymes such as catalase and dismutase.

Luteolin is further known to raise the level of reduced glutathione and upregulated the expression of glutathione synthetase which is a potent antioxidant [8] (Furthermore, it has been observed that luteolin induces apoptosis in human colon cancer cells by activating mitogen-activated protein kinase signaling pathway that plays an important role in programmed cell death [9]. In vivo experiments on animal models with diethylnitrosamine-induced liver cancer indicated amelioration in the levels of enzymatic oxidants such as catalase, superoxide dismutase; marker enzymes such as alanine/ aspartate transaminases; α-fetoprotein; and accumulation of lipid peroxides in liver tissues and plasma [10].

Besides, several metals and metal ions are known to trigger a series of events that cater to the production of ROS and generate oxidative stress in cells. Free radical scavenging by metal chelation serves as an attractive approach for exerting the antioxidant effect. Especially, the low molecular weight metal chelators have received a considerable attention as therapeutics that function by mitigating the oxidative stress generated by metal ions by scavenging the free radicals generated thereof. Luteolin serves as a good metal-chelating agent owing to the presence of dihydroxyl substituents on the aromatic ring framework. These groups can chelate a variety of divalent, trivalent and tetravalent metal ions including Zn(II), V(II), Cu(II), Fe(II), Sn(II), Fe(III), Cr(III), Vn(IV), and Mo(IV) [11]. Recently, the complexation of Mn(II) with luteolin has been reported through the carbonyl group and the adjacent hydroxyl group of latter [12]. This complex has been reported to show enhanced antioxidant activity as compared to the parent molecule itself. Luteolin-Mn(II) complex reversibly inhibited the xanthine oxidase in competitive manner, which is a main enzyme involved in the production of reactive oxygen species [13].

Upon exposure to different ultraviolet (UV-A) radiations, the human skin fibroblasts exhibit autophagy and a burst release of ROS. Incubation with micromolar concentration of luteolin is known to protect human skin fibroblasts from ultraviolet (UV-A) radiation by decreased autophagy as ascertained by fluorescence and transmission electron microscopy. The ROS levels also lowered as indicated by flow cytometry. Furthermore, the treatment with luteolin led to downregulation of the expression of hypoxia-inducible factor-1α and autophagy-associated proteins, Beclin 1, and LC3 in UV-A irradiated human skin fibroblasts as indicated by western blotting assay [14].

The protective effect of luteolin against the photoaging effect of UV-B radiation is noteworthy. The irradiation of human dermal fibroblasts with UV-B led to raised ROS levels in the skin and tissues causing a significant damage to the skin of animal models. As observed in the hematoxylin–eosin and Masson staining. The detection of ROS levels was done with the help of dihydroethidium (DHE) and dichlorofluorescein (DCF) fluorescent probes. Luteolin reportedly relieved UV-B induced wrinkle formation and erythema and improved cell viability. Furthermore, luteolin lowered the levels of oxidative stress, and downregulated the activation of matrix metalloproteinases (MMPs). Luteolin provides protection to the ageing skin cells under the influence of UV-B radiation by targeting SIRT3/ROS/MAPK pathways (Mu et al. 2021).

Luteolin exhibits pro-oxidant potential that plays a critical role in inducing apoptosis in cancer cells. Ju et al. [15] provided evidence on the luteolin-induced accumulation of ROS that modulates the expression of TNF-activated pathways in lung cancer cells. The expression of NF-kB is downregulated, while the expression of c-Jun N-terminal kinase is potentiated that instigates apoptosis in lung cancer cells induced by tumor necrosis factor. Moreover, luteolin further triggered an early phase accumulation of ROS due to the suppression of the activity of cellular superoxide dismutase.

Luteolin extracted from the leaves of Clerodendrum cryptophyllum Turcz exerts antioxidant activity and negligible cytotoxicity or genotoxicity in TBHP (tert-Butyl hydroperoxide)-sensitized HepG2 cells. Preincubation of cells with 1–40 µM concentration of Luteolin followed by their direct exposure to TBHP significantly improved the cell viability in a dose dependent manner. Luteolin reportedly demonstrated an optimal 43.7% inhibition of the accumulation of ROS, 24.5% decrease in malondialdehyde levels, and 38.7% lowering of lactate dehydrogenase levels at a concentration of 30 µM. Similarly, the expression of superoxide dismutase ameliorated by 73.7%, while the activity of glutathione improved by 72.3% at the same concentration of luteolin. The results from western blot assay showed an upregulation of procaspase-3 and a downregulation of cleaved caspase-3 that eventually resulted in the countering of TBHP-instigated oxidative stress [16].

Oxidative stress has been found to be a major contributing factor towards the progression of neurodegeneration and ensuing disorders such as Alzheimer’s disease and Huntington’s disease. Luteolin has been reported to exert antioxidant effect and neuroprotective effect in sodium nitroprusside-sensitized animals. The coadministration of 3–30 nM luteolin and 10 nM sodium nitroprusside in corpus striatum provides defense against ROS-mediated motor dysfunction and brain damage in animals by Fe2+ induced lipid peroxidation in homogenate of mouse brain.

The similar effect is achieved for 600–1200 mg/kg of orally administered luteolin. Encouraging results obtained from ferrozine assay validated that luteolin at a concentration of 30–100 µg/ml shows Fe2+ chelating property and potent DPPH radical scavenging ability at 1–100 µg/ml concentration. These inferences indicated that administration of luteolin by oral or intrastriatal routes provides defense to the mice brain against sodium nitroprusside-induced oxidative damage due to the free radical scavenging and chelating effect of luteolin [17].

Poor bioavailability of luteolin limits its optimal therapeutic efficacy and bioactivity. In order to improve these parameters, mono-acylated derivatives of luteolin have been developed to display radical scavenging activity in addition to showing antiproliferative activity against MDA-MB-231 breast cancer cell lines and HCT116 colon cancer cell lines. The acylation of hydroxyl groups improves the lipophilicity of the test compounds that improves their bioavailability. Furthermore, the radical scavenging property of these derivatives against 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical was retained as that of the parent luteolin molecule while keeping Trolox as standard [18].

Luteolin as inhibitor of cell cycle progression

Cyclin-dependent kinases (CDK)-cyclin complexes regulate the cell cycle responsible for cell growth, development, and differentiation. The dysregulation of cell cycle transforms normal cells to tumor cells. Considering its association towards the development of tumorigenesis, the chemical agents that arrest cell cycle progression have drawn a considerable attention towards the development of anticancer therapeutics [19].

Treatment of MDA-MB-231 cells with luteolin led to dose dependent arrest of cell cycle in S phase by reducing the levels of telomerase and by inhibiting the phosphorylation of NF-kB inhibitor α along with its target gene c-Myc. These events led to the suppression of the expression of human telomerase reverse transcriptase (hTERT) encoding for the catalytic subunit of telomerase. Also, luteolin suppressed the development of breast cancer cells and induced apoptosis to check their progression [20].

Park et al. [21] provided evidence for the arrest of cell cycle by luteolin by studying its anticancer effect on MCF-7 breast cancer cells. Incubation of cancer cells with luteolin caused morphological changes in nucleus and caused perturbation in the progression of cell cycle at sub-G1 and G1 phases in MCF-7 cells. Moreover, luteolin upregulated the expression of caspase cascades and death receptors, including DR5. Luteolin also augmented the activity of caspase-3/-8/-9 in a dose dependent manner and inactivated poly-ADP ribose polymerase (PARP), which is a prime factor that assists the cancer cells to repair themselves. Furthermore, luteolin triggered collapse of mitochondrial membrane potential followed by the release of cytochrome c. Eventually, Bax expression augments in the presence of luteolin, while the expression of Bcl-2 is inhibited. Overall, these results suggest the arresting of cell cycle and induction of apoptosis in cancer cells incubated with luteolin.

Treatment of HeLa cells with luteolin has been shown to exhibit cytotoxicity in a dose- and time-dependent manner. Luteolin also exhibited anti-proliferative activity as indicated by the accumulation of luteolin-incubated cells in sub-G1 phase of cell cycle. Treatment with luteolin causes depolarization of mitochondrial membrane potential that manifests cytotoxicity towards cancer cells. Furthermore, the expression of proapoptotic genes such as FAS, FADD, BAX, BAD, BOK, BID, TRADD upregulates, while the anti-apoptotic genes NAIP, BCL-2, and MCL-1 experience downregulation. The expression of cell cycle regulatory genes CDK2, CDKN2B, CCNE2, CDKN1A, and CDK4 decreased on incubation with luteolin.

At transcriptional level, the expression of MAPK1, MAPK3, MAP3K5, MAPK14, PIK3C2A, PIK3C2B, AKT1, AKT2, and ELK1 downregulated. Notably, the expression of PRAS 40 (p-Ther246), PDK1(pser241), PTEN (p-ser380), GSK3b (pser9), AKT (pser473), BAD (pser112), RISK2 (pser386), P70S6k (pThr421/ser424), ERK1 (pT202/Y204), ERK2 (pY185/Y187), and MTOR (pser2448) downregulated in the presence of luteolin in a dose-dependent manner. Overall, these results suggested the display of anti-proliferative and apoptosis triggering properties of luteolin due to the inhibition of MAPK and AKT pathways and due to the arresting of cell cycle by luteolin [22].

The mechanism of inhibition of cell cycle and pro-apoptotic effect of luteolin on human non-small-cell lung carcinoma cell lines A549 was analyzed by Cai et al. [23]. The flow cytometry investigations have revealed increased number of apoptotic cells and G2 phase cells indicating the non-progression of cells beyond G2 phase. The western blot assay indicated the activation of JNK by luteolin, augmented the production of Bax, and increased cleavage of procaspase-9 and caspase-3. The pretreatment of A549 cells with luteolin led to an inhibition of TNFα-mediated trans-nuclear translocation of NF-kB.

Luteolin is also found to arrest cell cycle in G2/M phase in addition to the induction of apoptosis in human colon cancer cells xenografts. The flow cytometric analysis has validated the observation that luteolin promotes cell cycle arrest in G2/M phase and induces apoptosis in LoVo human colon cancer cells in time- and dose-dependent manner. Similar observation is obtained with western blot analysis which revealed that luteolin posed inhibitory effect on cell proliferation on LoVo cells by arresting cell cycle at G2/M phase transition and inactivated cyclin B1 and cell division cycle 2. These events are mediated by cytochrome c and deoxyadenosine triphosphate-mediated activation of apoptotic protease activating factor 1. Further in vivo analysis suggested a decrease in the body weight of colon tumor mice. Overall, these findings indicated chemopreventive and chemotherapeutic effect of luteolin against human colon cancer [24].

Luteolin has been reported to exert cytotoxicity against human hepatocellular carcinoma cell lines HepG2, PLC/PRF/5, HA22T/VGH, and SK-Hep-1. These cell lines on treatment with luteolin demonstrate typical changes in apoptosis with specific DNA laddering pattern. Luteolin reportedly activated caspase-3, and aggravated Bax protein with a simultaneous lowering of Bcl-XL levels. This evidence supports the induction of apoptosis in selected cancer cell lines. Luteolin also mediated arrest of cell cycle in Go/G1 phase that results in anticancer effect [25].

Similar observation has been reported on human breast cancer cell line MDA-MB-453 via regulation of cell cycle and induction of apoptosis and antiproliferative effect. Treatment of these cancer cell lines with luteolin at various doses led to a remarkable lowering of cancer cell growth in a time dependent manner. Notably, the incubation of cancer cells with luteolin results in a considerable decrease in the population of sub-G1 phase cells thereby indicating the arrest of cell cycle in this phase [26]. Luteolin has been investigated to show cytotoxicity activity on human immortalized keratinocytes (HaCaT), and human melanoma cells (A375). Luteolin exerts cell cycle arrest and apoptosis in these cell lines as indicated in the flow cytometry and cellular DNA fragmentation assay. Incubation of the test cancer cell lines with luteolin for 24 h led to accumulation of cells in G2/M phase for HaCaT cells and in G0/G1 phase for A375 cells. The inhibition of cell proliferation, induction of apoptosis, and triggering of cell cycle arrest by luteolin is responsible for the programmed cell death of skin cancer cells [27].

Luteolin-induced autophagy

Autophagy has been identified as a potential approach for limiting the proliferation and viability of cancer cells. Autophagy is a catabolic process that provides energy during starvation. This energy is derived from the degradation of aged cells and organelles, in addition to the toxic cellular components. Autophagy begins with the disruption of mitochondria and various organelles in cytoplasm. The main role of autophagy is to maintain homeostasis of eukaryotic cells during abiotic and biotic stress. The cellular mechanism of autophagy includes the transferring of damaged cells and organelles and deleterious proteins into lysosomes for the onset of their degradation. The simple end products of degradation, such as amino acids are eventually recycled in the cells.

Owing to its role in maintaining normal functioning and metabolism of healthy cells, autophagy has been identified as a potential approach in the contemporary anticancer therapy. Autophagy plays a dual role of tumor suppression, in addition to its promotion and proliferation depending on the regulation of oncogenic factors such as mTOR, AMPK, PI3K, and AKT. The optimal operation of autophagy plays an important role for the suppression of tumor by reducing the damaged cellular components for upholding the cellular homeostasis.

Reportedly, the autophagy related gene Beclin 1 (BECN1), which plays an important role in the formation of phagophore and tumor suppression, is found to deplete in the human ovarian, breast, prostate cancers, as well as hepatocellular carcinoma and squamous-cell carcinomas. The same has been ascertained in tumor animal models and cancer-cell lines where a downregulation of BECN1 manifests a marked reduction in autophagy followed by enhanced cell proliferation.

Luteolin is known to regulate the expression of Beclin 1, which is an important regulator of autophagy during the nucleation step that results in tumor suppression. Luteolin is also known to regulate the expression of immunoglobulin proteins that bind to endoplasmic reticulum chaperone, and to activate the endoplasmic reticulum stress sensors which includes phosphorylation of eukaryotic initiation factor 2α and splicing of Xbox-binding protein 1 mRNA. Similarly, luteolin exerts autophagy at the elongation step by downregulation of LC3, which is a marker of autophagosomes and found to express in gastrointestinal cancers.

P53 signaling is closely related with the induction or suppression of autophagy thereby presenting a desirable approach towards the anticancer therapy. Functioning as a nuclear transcription factor and mediating the transactivation of proapoptotic, cell cycle arresting proautophagic genes, p53 is considered as a master regulator of autophagy depending on its subcellular localization. Yoo et al. [28] reported the anticancer effect of luteolin due to the induction of apoptosis and autophagy in colon cancer cells. In the presence of luteolin, the HCT116 cells showed heightened phosphorylation of p53 and p53 target gene expression eventually resulting in apoptosis and cell cycle arrest. Autophagy is induced by luteolin in p53 wild-type cells and not in mutant p53 cells. This evidence suggests that autophagy by luteolin is p53 dependent.

Evidence for the induction of apoptosis and autophagy in human hepatocellular cancer Hep3B cells was provided by Lee et al. [29]. To study the effect of luteolin on autophagy, the protein levels of LC3-II and p62 which are considered as markers of autophagy was measured. The levels of LC-II increase on the formation of autophagosomal membranes due to the conjugation of phosphatidylethanolamine with cytosolic LC3. The fusion of lysosomes with autophagosome leads to the degradation of receptor protein p62 along with the LC3-II proteins lying inside and outside of the autophagosome. Therefore, the level of p62 is reduced with a simultaneous increase in the LC3-II levels during autophagy.

Similarly, the protein levels of p62 downregulated while that of LC3-II is upregulated following the luteolin treatment in p53 wild type HepG2 cells indicating the induction of autophagy. This evidence was further validated by analyzing the number of viable cells in the presence of luteolin and autophagy inhibitors 3-methyladenine and chloroquine where the number of viable cells considerably lowered. Luteolin-induced autophagy in cancer cells was further validated by Lee et al. [30]. The A172 and U-373MG cells treated with luteolin showed reduced viability in concentration- and dose-dependent manner. At a concentration above 100 µM, the nucleus of these cells undergoes fragmentation and characteristic morphological changes start to appear that confirm the onset of apoptosis. Notably, the fragmentation of apoptosis-related factors caspase-3, and poly(ADP-ribose) polymerase (PARP) was observed that further confirms the onset of apoptosis at 50 µM concentration.

Luteolin treatment reportedly increased the number of intracellular autophagosomes, as indicated by an increased expression of Beclin 1, and conversion of LC3B-I to LC3B-II in hepatocellular carcinoma SMMC-7721 cells. These events suggest the onset of autophagy in cancer cells followed by their exposure to luteolin which was validated by a reduction in luteolin-induced autophagy in the presence of autophagy inhibitor chloroquine. However, the effect of autophagy was only partial as cell cycle arrest and induction of apoptosis were also noticed as contributing factors [31].

Luteolin has been reported to sensitize the human liver cancer cells towards autophagy induced by tumor necrosis factorrelated apoptosisinducing ligand (TRAIL), which is a type II transmembrane protein of the TNF superfamily. TRAIL induces apoptosis in cancer cells without harming the healthy cells that make it a desirable target for the treatment of various cancer types. However, some cancers develop resistance towards TRAIL-mediated apoptosis which necessitate their sensitization. Treatment of TRAIL-resistant Huh7 cells with luteolin and TRAIL results in synergistic effect on cells.

Reportedly, TRAIL prompts the formation of autophagosomes and its effect on promoting autophagy is determined by the expression of autophagy related genes (ATGs) including Atg5, Atg7, and beclin-1 however, the silencing of JNK pathway results in the attenuation of TRAIL-induced expression of ATGs. In vivo investigations on A549 cell lines established TRAIL-induced autophagy by modulation of ATG expression via JNK pathway that further causes apoptosis and inhibition of cell proliferation. Similarly, luteolin induces autophagic flux in the liver cancer cells that is lowered after the application of autophagy inhibitors such as chloroquine.

The treatment of cancer cells with genetically modified autophagy-related 5 siRNA caused a marked reduction in luteolin-triggered sensitization effect on TRAIL. Pre-treatment of cells with c-Jun N-terminal kinase (JNK) inhibitor SP600125 caused a remarkable inhibition of luteolin-instigated surge of the expression of DR5, which suggests the relation between promotion of DR5 expression by JNK activation [32].

Bcl-2 presents a molecular link between apoptosis and autophagy and its downregulation is known to activate the expression of Beclin-1, which is key regulator of apoptosis and autophagy. Luteolin is also reported to induce apoptosis and autophagy in mouse macrophage ANA-1 cells through Bcl-2 pathway. Incubation of cells with luteolin lowered their viability and led to the downregulation of Bcl-2 expression, induced autophagy and apoptosis, while upregulating the expression of caspase-3/-8. Furthermore, the levels of ATG12, ATG7, and LC3-1 increased while suppression in the levels of Beclin-1 occurs. Treatment with luteolin activated p38, Akt, and JNK signaling pathways that play an important role in autophagy and apoptosis. The pathways through which luteolin regulates autophagy and apoptosis are depicted in Fig. 2.

Fig. 2
figure 2

Regulation of autophagy and apoptosis by luteolin

Full size image

Luteolin in the management of various types of cancers

The effects of the Luteolin in various types of cancers summarized in the Table 1.

Table 1 Effects of the luteolin in various types of cancers
Full size table

Conclusion

Nature-derived polyphenolics have been long known for their medicinal competence and therapeutic precedence with minimal side effects and toxicity. The physiological benevolence of natural chemicals such as luteolin has been attracted considerable attention for its application in the mitigation of deadly diseases. Luteolin targets multifaceted cancer pathways by creating redox stress, ROS generation, cell cycle arrest, inducing autophagy, onset of apoptosis, inhibition of cell proliferation, eventually leading to cancer cell death. Luteolin is known to exert synergistic inhibition of cancer progression with anticancer drugs, and its anticancer profile is successfully applied for the management of colon cancer, breast cancer, prostate cancer, and liver cancer. The parent structure of luteolin has been chemically modified to further achieve enhanced bioavailability for an optimal therapeutic efficacy. However, the mechanism of inhibition of cancer progression by luteolin is still not well elucidated. The untangling of luteolin-mediated anticancer effect can serve as a promising approach for the development of luteolin as the anticancer drug of future. Similarly, luteolin is safer however some reports have indicated the worsening of chemically induced colitis in animal models that raises the necessity address the safety profile of luteolin.

Availability of  data and materials

Not applicable.

References

  1. Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796.

    Article  CAS  Google Scholar 

  2. George BP, Chandran R, Abrahamse H. Role of Phytochemicals in Cancer Chemoprevention: insights. Antioxidants  2021;10(9):1455.

    Article  CAS  Google Scholar 

  3. Ashrafizadeh M, Ahmadi Z, Farkhondeh T, Samarghandian S. Autophagy regulation using luteolin: new insight into its anti-tumor activity. Cancer Cell Int. 2020;20(1):537.

    Article  CAS  Google Scholar 

  4. Chen HI, Hu WS, Hung MY, Ou HC, Huang SH, Hsu PT, Day CH, Lin KH, Viswanadha VP, Kuo WW, et al. Protective effects of luteolin against oxidative stress and mitochondrial dysfunction in endothelial cells. Nutr Metab Cardiovasc Dis. 2020;30(6):1032–43.

    Article  CAS  Google Scholar 

  5. Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariati MA, Khan IA, Imran A, Orhan IE, Rizwan M, Atif M, et al. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed Pharmacother. 2019;112:108612.

    Article  CAS  Google Scholar 

  6. Tan X, Yang Y, Xu J, Zhang P, Deng R, Mao Y, He J, Chen Y, Zhang Y, Ding J, et al. Luteolin exerts Neuroprotection via Modulation of the p62/Keap1/Nrf2 pathway in Intracerebral Hemorrhage. Front Pharmacol. 2019;10:1551.

    Article  CAS  Google Scholar 

  7. Kang KA, Piao MJ, Ryu YS, Hyun YJ, Park JE, Shilnikova K, Zhen AX, Kang HK, Koh YS, Jeong YJ, et al. Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. Int J Oncol. 2017;51(4):1169–78.

    Article  CAS  Google Scholar 

  8. Raj Rai S, Bhattacharyya C, Sarkar A, Chakraborty S, Sircar E, Dutta S, Sengupta R. Glutathione: role in Oxidative/Nitrosative stress, antioxidant defense, and treatments. ChemistrySelect. 2021;6(18):4566–90.

    Article  CAS  Google Scholar 

  9. Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 2020;21(7):2346.

    Article  CAS  Google Scholar 

  10. Zhang Q, Yang J, Wang J. Modulatory effect of luteolin on redox homeostasis and inflammatory cytokines in a mouse model of liver cancer. Oncol Lett. 2016;12(6):4767–72.

    Article  CAS  Google Scholar 

  11. Selvaraj S, Krishnaswamy S, Devashya V, Sethuraman S, Krishnan UM. Flavonoid-metal ion complexes: a novel class of therapeutic agents. Med Res Rev. 2014;34(4):677–702.

    Article  CAS  Google Scholar 

  12. Dong H, Yang X, He J, Cai S, Xiao K, Zhu L. Enhanced antioxidant activity, antibacterial activity and hypoglycemic effect of luteolin by complexation with manganese(ii) and its inhibition kinetics on xanthine oxidase. RSC Adv. 2017;7(84):53385–95.

    Article  CAS  Google Scholar 

  13. Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation. Redox Biol. 2013;1(1):353–8.

    Article  CAS  Google Scholar 

  14. Yan M, Liu Z, Yang H, Li C, Chen H, Liu Y, Zhao M, Zhu Y. Luteolin decreases the UVA–induced autophagy of human skin fibroblasts by scavenging ROS. Mol Med Rep. 2016;14(3):1986–92.

    Article  CAS  Google Scholar 

  15. Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappab pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol. 2007;71(5):1381–8.

    Article  CAS  Google Scholar 

  16. Li G, Zhou J, Sun M, Cen J, Xu J. Role of luteolin extracted from Clerodendrum cyrtophyllum Turcz leaves in protecting HepG2 cells from TBHP-induced oxidative stress and its cytotoxicity, genotoxicity. J Funct Foods. 2020;74:104196.

    Article  CAS  Google Scholar 

  17. Nazari QA, Kume T, Takada-Takatori Y, Izumi Y, Akaike A. Protective effect of luteolin on an oxidative-stress model induced by microinjection of sodium nitroprusside in mice. J Pharmacol Sci. 2013;122(2):109–17.

    Article  CAS  Google Scholar 

  18. Lo S, Leung E, Fedrizzi B, Barker D. Syntheses of mono-acylated luteolin derivatives, evaluation of their antiproliferative and radical scavenging activities and implications on their oral bioavailability. Sci Rep. 2021;11(1):12595.

    Article  CAS  Google Scholar 

  19. Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14(4):348–62.

    Article  CAS  Google Scholar 

  20. Huang L, Jin K, Lan H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol Lett. 2019;17(4):3842–50.

    CAS  Google Scholar 

  21. Park SH, Ham S, Kwon TH, Kim MS, Lee DH, Kang JW, Oh SR, Yoon DY. Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol. 2014;33(3):219–31.

    Article  Google Scholar 

  22. Raina R, Pramodh S, Rais N, Haque S, Shafarin J, Bajbouj K, Hamad M, Hussain A. Luteolin inhibits proliferation, triggers apoptosis and modulates Akt/mTOR and MAP kinase pathways in HeLa cells. Oncol Lett. 2021;21(3):192.

    Article  CAS  Google Scholar 

  23. Cai X, Ye T, Liu C, Lu W, Lu M, Zhang J, Wang M, Cao P. Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol In Vitro. 2011;25(7):1385–91.

    Article  CAS  Google Scholar 

  24. Chen Z, Zhang B, Gao F, Shi R. Modulation of G(2)/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts. Oncol Lett. 2018;15(2):1559–65.

    Google Scholar 

  25. Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L, Lin C. Increase of Bax/ Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci. 2005;76(16):1883–93.

    Article  CAS  Google Scholar 

  26. Choi EJ, Bae SM, Ahn WS. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch Pharm Res. 2008;31(10):1281–5.

    Article  CAS  Google Scholar 

  27. George VC, Naveen Kumar DR, Suresh PK, Kumar S, Kumar RA. Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCaT and A375 cells. Asian Pac J Cancer Prev. 2013;14(2):631–7.

    Article  Google Scholar 

  28. Yoo HS, Won SB, Kwon YH. Luteolin induces apoptosis and autophagy in HCT116 Colon cancer cells via p53-Dependent pathway. Nutr Cancer. 2022;74(2):677–86.

    Article  CAS  Google Scholar 

  29. Lee Y, Kwon YH. Regulation of apoptosis and autophagy by luteolin in human hepatocellular cancer Hep3B cells. Biochem Biophys Res Commun. 2019;517(4):617–22.

    Article  CAS  Google Scholar 

  30. Lee HS, Park BS, Kang HM, Kim JH, Shin SH, Kim IR. Role of Luteolin-Induced apoptosis and autophagy in human glioblastoma cell lines. Medicina. 2021;57(9):879.

    Article  Google Scholar 

  31. Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F, Zhang Y. Luteolin promotes cell apoptosis by inducing Autophagy in Hepatocellular Carcinoma. Cell Physiol Biochem. 2017;43(5):1803–12.

    Article  CAS  Google Scholar 

  32. Nazim UM, Park SY. Luteolin sensitizes human liver cancer cells to TRAIL–induced apoptosis via autophagy and JNK–mediated death receptor 5 upregulation. Int J Oncol. 2019;54(2):665–72.

    CAS  Google Scholar 

  33. Pandurangan AK, Kumar SA, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: involvement of iNOS and COX-2. Pharmacogn Mag. 2014;10(Suppl 2):306–10.

    Google Scholar 

  34. Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colorectal cancer through activation of Nrf2 signaling. Toxicol Mech Methods. 2014;24(1):13–20.

    Article  CAS  Google Scholar 

  35. Pandurangan AK, Dharmalingam P, Sadagopan SK, Ganapasam S. Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis. Hum Exp Toxicol. 2014;33(11):1176–85.

    Article  CAS  Google Scholar 

  36. Lim DY, Cho HJ, Kim J, Nho CW, Lee KW, Park JH. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells. BMC Gastroenterol. 2012;12:9.

    Article  CAS  Google Scholar 

  37. Potočnjak I, Šimić L, Gobin I, Vukelić I, Domitrović R. Antitumor activity of luteolin in human colon cancer SW620 cells is mediated by the ERK/FOXO3a signaling pathway. Toxicol In Vitro. 2020;66:104852.

    Article  Google Scholar 

  38. Kang KA, Piao MJ, Hyun YJ, Zhen AX, Cho SJ, Ahn MJ, Yi JM, Hyun JW. Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019;51(4):1–14.

    Article  Google Scholar 

  39. Yao Q, Luo Y, Sun L, Wang H, Li W. Luteolin suppressed growth of colon tumor via inflammation, oxidative stress, and NLRP3/IL-1β signal axis. Pharmacognosy Magazine. 2022;18(78):494–501.

    CAS  Google Scholar 

  40. Zuo T, Yue Y, Wang X, Li H, Yan S. Luteolin Relieved DSS-Induced colitis in mice via HMGB1-TLR-NF-κB signaling pathway. Inflammation. 2021;44(2):570–9.

    Article  CAS  Google Scholar 

  41. Aromokeye R, Si H. Combined Curcumin and Luteolin synergistically inhibit Colon Cancer Associated with Notch1 and TGF-β signaling pathways in cultured cells and xenograft mice. Cancers. 2022;14(12):3001.

    Article  CAS  Google Scholar 

  42. Zuo Q, Wu R, Xiao X, Yang C, Yang Y, Wang C, Lin L, Kong AN. The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells. J Cell Biochem. 2018;119(11):9573–82.

    Article  CAS  Google Scholar 

  43. Kollur SP, Prasad SK, Pradeep S, Veerapur R, Patil SS, Amachawadi RG, Lamraoui SRP, Al-Kheraif G, Elgorban AAAM, et al. Luteolin-fabricated ZnO nanostructures showed PLK-1 mediated Anti-Breast Cancer Activity. Biomolecules. 2021;11(3):385.

    Article  CAS  Google Scholar 

  44. Wu HT, Lin J, Liu YE, Chen HF, Hsu KW, Lin SH, Peng KY, Lin KJ, Hsieh CC, Chen DR. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. Phytomedicine. 2021;81:153437.

    Article  CAS  Google Scholar 

  45. Gao G, Ge R, Li Y, Liu S. Luteolin exhibits anti-breast cancer property through up-regulating miR-203. Artif Cells Nanomed Biotechnol. 2019;47(1):3265–71.

    Article  CAS  Google Scholar 

  46. Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, Li H. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol Rep. 2017;37(2):895–902.

    Article  CAS  Google Scholar 

  47. Lee J, Park SH, Lee J, Chun H, Choi MK, Yoon JH, Pham TH, Kim KH, Kwon T, Ryu HW, et al. Differential effects of luteolin and its glycosides on invasion and apoptosis in MDA-MB-231 triple-negative breast cancer cells. Excli J. 2019;18:750–63.

    Google Scholar 

  48. Cao D, Zhu GY, Lu Y, Yang A, Chen D, Huang HJ, Peng SX, Chen LW, Li YW. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Biomed Pharmacother. 2020;129:110462.

    Article  CAS  Google Scholar 

  49. Sun DW, Zhang HD, Mao L, Mao CF, Chen W, Cui M, Ma R, Cao HX, Jing CW, Wang Z, et al. Luteolin inhibits breast Cancer Development and Progression in Vitro and in vivo by suppressing Notch Signaling and regulating MiRNAs. Cell Physiol Biochem. 2015;37(5):1693–711.

    Article  CAS  Google Scholar 

  50. Dong X, Zhang J, Yang F, Wu J, Cai R, Wang T, Zhang J. Effect of luteolin on the methylation status of the OPCML gene and cell growth in breast cancer cells. Exp Ther Med. 2018;16(4):3186–94.

    Google Scholar 

  51. Cook MT, Liang Y, Besch-Williford C, Hyder SM. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer  2017;9:9–19.

    CAS  Google Scholar 

  52. Tsai KJ, Tsai HY, Tsai CC, Chen TY, Hsieh TH, Chen CL, Mbuyisa L, Huang YB, Lin MW. Luteolin inhibits breast Cancer stemness and enhances chemosensitivity through the Nrf2-Mediated pathway. Molecules. 2021;26(21):6452.

    Article  CAS  Google Scholar 

  53. Masraksa W, Tanasawet S, Hutamekalin P, Wongtawatchai T, Sukketsiri W. Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway. Nutr Res Pract. 2020;14(2):127–33.

    Article  CAS  Google Scholar 

  54. Yu Q, Zhang M, Ying Q, Xie X, Yue S, Tong B, Wei Q, Bai Z, Ma L. Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment. Cell Death Dis. 2019;10(3):218.

    Article  Google Scholar 

  55. Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett. 2021;515:36–48.

    Article  CAS  Google Scholar 

  56. Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X, Wu MH. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p. Int J Mol Sci. 2018;19(2):447.

    Article  Google Scholar 

  57. Zhang M, Wang R, Tian J, Song M, Zhao R, Liu K, Zhu F, Shim JH, Dong Z, Lee MH. Targeting LIMK1 with luteolin inhibits the growth of lung cancer in vitro and in vivo. J Cell Mol Med. 2021;25(12):5560–71.

    Article  CAS  Google Scholar 

  58. Hong Z, Cao X, Li N, Zhang Y, Lan L, Zhou Y, Pan X, Shen L, Yin Z, Luo L. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance. Br J Pharmacol. 2014;171(11):2842–53.

    Article  CAS  Google Scholar 

  59. Zhao Y, Yang G, Ren D, Zhang X, Yin Q, Sun X. Luteolin suppresses growth and migration of human lung cancer cells. Mol Biol Rep. 2011;38(2):1115–9.

    Article  CAS  Google Scholar 

  60. Chen W, Weng S, Zhang F, Allen S, Li X, Bao L, Lam RH, Macoska JA, Merajver SD, Fu J. Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano. 2013;7(1):566–75.

    Article  CAS  Google Scholar 

  61. Zhou YS, Cui Y, Zheng JX, Quan YQ, Wu SX, Xu H, Han Y. Luteolin relieves lung cancer-induced bone pain by inhibiting NLRP3 inflammasomes and glial activation in the spinal dorsal horn in mice. Phytomedicine. 2022;96:153910.

    Article  CAS  Google Scholar 

  62. Seo Y, Ryu K, Park J, Jeon DK, Jo S, Lee HK, Namkung W. Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells. PLoS ONE. 2017;12(3):e0174935.

    Article  Google Scholar 

  63. Zhou Q, Yan B, Hu X, Li XB, Zhang J, Fang J. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther. 2009;8(6):1684–91.

    Article  CAS  Google Scholar 

  64. Han K, Lang T, Zhang Z, Zhang Y, Sun Y, Shen Z, Beuerman RW, Zhou L, Min D. Luteolin attenuates wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. Sci Rep. 2018;8(1):8537.

    Article  Google Scholar 

  65. Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, et al. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS ONE. 2012;7(12):e52279.

    Article  CAS  Google Scholar 

  66. Han K, Meng W, Zhang JJ, Zhou Y, Wang YL, Su Y, Lin SC, Gan ZH, Sun YN, Min DL. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 2016;9:3085–94.

    Article  CAS  Google Scholar 

  67. Sakurai MA, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, Tabara H, Inoue T, Hagiyama M, Ito A, et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS ONE. 2014;9(6):e100124.

    Article  Google Scholar 

  68. Naiki-Ito A, Naiki T, Kato H, Iida K, Etani T, Nagayasu Y, Suzuki S, Yamashita Y, Inaguma S, Onishi M, et al. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. Carcinogenesis. 2019;41(8):1145–57.

    Article  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Chemistry, University of Petroleum & Energy Studies, Dehradun, 248007, India

    Parteek Prasher

  2. Department of Chemistry, Uttaranchal University, Dehradun, 248007, India

    Mousmee Sharma

  3. School of Pharmacy and Pharmaceutical Science, Lovely Professional University, Phagwara, India

    Sachin Kumar Singh & Monica Gulati

  4. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia

    Sachin Kumar Singh, Monica Gulati, Gabriele De Rubis & Kamal Dua

  5. Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia

    Dinesh Kumar Chellappan

  6. Departamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuna Mackenna 4860, Macul, 7820436, Santiago, Chile

    Flavia Zacconi

  7. Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, 7820436, Santiago, Chile

    Flavia Zacconi

  8. Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, Australia

    Gabriele De Rubis & Kamal Dua

  9. School of Pharmacy, Suresh Gyan Vihar University, Jaipur, Rajasthan, India

    Gaurav Gupta

  10. Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador

    Javad Sharifi-Rad

  11. Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China

    William C. Cho

  12. Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

    Gaurav Gupta

  13. Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India

    Gaurav Gupta

Authors
  1. Parteek Prasher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mousmee Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sachin Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monica Gulati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dinesh Kumar Chellappan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Flavia Zacconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gabriele De Rubis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gaurav Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Javad Sharifi-Rad
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. William C. Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kamal Dua
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas. That is, revising or critically reviewing the article; giving final approval of the version to be published; agreeing on the journal to which the article has been submitted; and, confirming to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Javad Sharifi-Rad, William C. Cho or Kamal Dua.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Authors wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prasher, P., Sharma, M., Singh, S.K. et al. Luteolin: a flavonoid with a multifaceted anticancer potential. Cancer Cell Int 22, 386 (2022). https://doi.org/10.1186/s12935-022-02808-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-022-02808-3

Cancer Cell International

ISSN: 1475-2867

Contact us